U.S. Markets open in 4 hrs 6 mins
S&P Futures
3,351.75-16.00(-0.48%)Dow Futures
27,625.00-198.00(-0.71%)Nasdaq Futures
11,158.25-17.00(-0.15%)
ImmunoGen, Inc. (IMGN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.8300-0.0300 (-0.78%)
At close: 4:00PM EDT
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 3.8600 |
| Open | 3.8400 |
| Bid | 3.4500 x 2900 |
| Ask | 4.2000 x 2200 |
| Day's Range | 3.7600 - 3.8500 |
| 52 Week Range | 1.9500 - 7.0700 |
| Volume | 1,406,186 |
| Avg. Volume | 2,273,418 |
| Market Cap | 668.496M |
| Beta (5Y Monthly) | 2.34 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4400 |
| Earnings Date | Oct 30, 2020 - Nov 03, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.96 |
- Insider Monkey
Did Hedge Funds Make The Right Call On ImmunoGen, Inc. (IMGN) ?
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find articles about an individual hedge fund's trades on numerous financial […]
- Business Wire
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Zacks
ImmunoGen (IMGN) Q2 Earnings and Sales Beat, Shares Down
ImmunoGen (IMGN) reports encouraging second-quarter results. Top-line data from pivotal study on its lead candidate, mirvetuximab soravtansine, likely to be delayed by six to eight weeks.
© 2020 Verizon Media. All rights reserved.
